BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw strong trading volume on Friday . 1,890,077 shares were traded during mid-day trading, a decline of 16% from the previous session’s volume of 2,262,210 shares.The stock last traded at $93.40 and had previously closed at $89.03.

A number of research analysts have recently issued reports on BMRN shares. Cowen and Company reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Sunday, April 17th. Royal Bank Of Canada reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 31st. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $126.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, June 1st. Leerink Swann reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, June 1st. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating and set a $99.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, June 1st. Three equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $122.96.

The stock has a 50 day moving average price of $84.27 and a 200 day moving average price of $83.96. The firm’s market capitalization is $14.95 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, April 28th. The company reported ($0.53) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.32. The firm had revenue of $236.70 million for the quarter, compared to analysts’ expectations of $240.21 million. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.43) earnings per share. On average, analysts predict that BioMarin Pharmaceutical Inc. will post ($2.84) earnings per share for the current fiscal year.

In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 2,167 shares of the business’s stock in a transaction on Thursday, July 7th. The stock was sold at an average price of $90.00, for a total transaction of $195,030.00. Following the sale, the executive vice president now directly owns 72,836 shares in the company, valued at $6,555,240. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Daniel K. Spiegelman sold 20,841 shares of the business’s stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $89.88, for a total value of $1,873,189.08. Following the sale, the chief financial officer now owns 71,235 shares in the company, valued at $6,402,601.80. The disclosure for this sale can be found here.

A number of hedge funds have recently bought and sold shares of BMRN. Vanguard Group Inc. increased its stake in BioMarin Pharmaceutical by 3.3% in the fourth quarter. Vanguard Group Inc. now owns 11,195,877 shares of the company’s stock worth $1,172,880,000 after buying an additional 355,727 shares during the last quarter. Victory Capital Management Inc. increased its stake in BioMarin Pharmaceutical by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 1,336,685 shares of the company’s stock worth $140,031,000 after buying an additional 6,782 shares during the last quarter. Mizuho Trust & Banking Co. Ltd. increased its stake in BioMarin Pharmaceutical by 0.3% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 233,477 shares of the company’s stock worth $24,695,000 after buying an additional 802 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in BioMarin Pharmaceutical by 5.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 153,926 shares of the company’s stock worth $16,127,000 after buying an additional 7,529 shares during the last quarter. Finally, Jennison Associates increased its stake in BioMarin Pharmaceutical by 25.0% in the third quarter. Jennison Associates now owns 150,000 shares of the company’s stock worth $15,798,000 after buying an additional 30,000 shares during the last quarter.

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.